KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis.

Felicia Cosman, Zhenxun Wang, Xiaodong Li, Steven R Cummings

J Bone Miner Res 40(6) 766-772

PMID39861972
PMCIDPMC12131232
DOI10.1093/jbmr/zjaf014
发表日期2025-01-25
入排依据:未发现恶性肿瘤人群证据。
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。
摘要

摘要

BMD levels achieved on osteoporosis treatment are predictive of subsequent fracture risk, and T-score >-2.5 has been proposed as a minimum treatment target for women with osteoporosis. Knowing the likelihood of attaining target T-scores with different medications for different baseline BMD levels can help determine appropriate initial treatment for individual patients. In this post hoc analysis, we estimated the probability of achieving a non-osteoporotic T-score (>-2.5 or ≥-2.0) at the TH or LS in postmenopausal women >60 yr old treated with denosumab for either 3 or 10 yr in the FREEDOM trial and its long-term extension. In women with baseline TH T-scores of -2.7, -3.0, and -3.5, the probabilities of achieving target T-scores >-2.5 with 3 yr of denosumab were 71%, 12%, and 0.1%, respectively. At LS, for baseline T-scores of -2.7, -3.0, and -3.5, the probabilities were 86%, 59%, and 11%, respectively. Longer treatment duration of up to 10 yr increased the probability of achieving target T-scores. The baseline T-scores that permitted at least 50% of women to achieve a target T-score >-2.5 were -2.8 at TH and -3.1 at LS after 3 yr and -3.0 at TH and -3.7 at LS after 10 yr of treatment. To achieve higher treatment targets (T-scores ≥ -2.0), overall probabilities were lower at both skeletal sites, particularly for TH, even with longer treatment duration. Our results demonstrate that the probability of achieving T-score targets with denosumab is dependent on baseline BMD, skeletal site, and treatment duration. Knowing the probability of achieving treatment targets for different baseline TH and LS T-scores can help determine whether denosumab is an appropriate first choice of treatment in individual patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Probabilities of achieving a T-score >−2.5 and ≥−2.0 at TH and LS with denosumab treatment over 1, 3, 5, and 10 yr by baseline T-score. Probability of achieving a TH T-score of >−2.5 (A) and ≥−2.0 (B) and an LS T-score of >−2.5 (C) and ≥−2.0 (D). * n = 227 for LS at year 1 from FREEDOM DXA substudy. Abbreviation: n , number of women who had baseline and evaluable BMD measurement at the given time point.
非 KM Figure